Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;34(4):e70095.
doi: 10.1111/exd.70095.

Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives

Marco Spadafora  1   2 , Serena Morsia  3 , Vito Giuseppe Di Lernia  4 , Shaniko Kaleci  2 , Giovanni Pellacani  5 , Caterina Longo  1   3
Affiliations

Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives

Marco Spadafora et al. Exp Dermatol. 2025 Apr.

Abstract

JAK inhibitors are used to treat various inflammatory skin diseases. However, systemic formulations are associated with an increased risk of major adverse events. Ruxolitinib 1.5% cream is a selective topical JAK1 and JAK2 inhibitor, which has recently been approved by EMA and MHRA for treating non-segmental vitiligo, while being FDA-approved for both vitiligo and atopic dermatitis. Recent literature has reported the off-label use of topical Ruxolitinib for several skin conditions, but data are mostly limited to single case reports and series and few prospective studies, with mixed results. We conducted a systematic review of the literature to investigate the potential efficacy of topical Ruxolitinib in various skin diseases in an off-label setting. The following keywords were used for searching the MEDLINE (Pubmed) and Scopus databases from inception to September 2024: "ruxolitinib cream and dermatology" and "topical ruxolitinib and dermatology". Reviews, articles not focusing on the main topic, books and book chapters, and articles with no English text were excluded. A total of 170 studies were screened, of which 112 fell within exclusion criteria and 58 were assessed for eligibility. Of these, 28 studies, published between 2012 and 2024, were selected. Ruxolitinib cream resulted in being used off-label mostly for treating lichenoid and granulomatous dermatoses, as well as alopecia areata. While for the former skin conditions, topical ruxolitinib proved to be effective and safe, results on efficacy in alopecia areata were controversial. Topical ruxolitinib might be a promising therapeutic option for lichenoid and granulomatous dermatoses. Noteworthily, despite the exciting results from the oral formulation, no consistent data were described for topical ruxolitinib in alopecia areata. Our review reported encouraging results for many inflammatory skin conditions that should be investigated in further studies.

Keywords: JAK inhibitors; dermatology; off‐label; ruxolitinib cream; topical ruxolitinib.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart describing the inclusion methodology applied in our review process (PRISMA flowchart).
FIGURE 2
FIGURE 2
Summary of skin conditions included in the analysis, categorised by the pathogenic mechanism.
FIGURE 3
FIGURE 3
Ruxolitinib mechanism of action on the JAK–STAT pathway.
See this image and copyright information in PMC

References

    1. Miot H. A., Criado P. R., de Castro C. C. S., Ianhez M., Talhari C., and Ramos P. M., “JAK‐STAT Pathway Inhibitors in Dermatology,” Anais Brasileiros de Dermatologia 98 (2023): 656–677. - PMC - PubMed
    1. Muddebihal A., Khurana A., and Sardana K., “JAK Inhibitors in Dermatology: The Road Travelled and Path Ahead, a Narrative Review,” Expert Review of Clinical Pharmacology 16 (2023): 279–295. - PubMed
    1. Klein B., Treudler R., and Simon J. C., “JAK‐Inhibitors in Dermatology ‐ Small Molecules, Big Impact? Overview of the Mechanism of Action, Previous Study Results and Potential Adverse Effects,” Journal der Deutschen Dermatologischen Gesellschaft 20 (2022): 19–24. - PubMed
    1. Wlassits R., Müller M., Fenzl K. H., Lamprecht T., and Erlacher L., “JAK‐Inhibitors ‐ A Story of Success and Adverse Events,” Open Access Rheumatology: Research and Reviews 16 (2024): 43–53. - PMC - PubMed
    1. Samuel C., Cornman H., Kambala A., and Kwatra S. G., “A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring,” Dermatologic Therapy 13 (2023): 729–749. - PMC - PubMed

Publication types